

| Press Release |

## **Recobia Therapeutics and Gustave Roussy Transfert Join Forces to Bring Next-Generation Oncology Therapies Closer to Patients**

**Strasbourg, France – March 31, 2026 – Recobia Therapeutics, a biotechnology-based start-up in Strasbourg, developing an innovative platform for subcutaneous (SC) administration of monoclonal antibodies and antibody-drug conjugates (ADCs) in oncology, today announced that Gustave Roussy Transfert, the valorisation and technology transfer affiliate of Gustave Roussy, the #1 cancer treatment centre in France and Europe, has become a shareholder of the company.**


### **Accelerate Innovation in Oncology Drug Delivery**

Gustave Roussy Transfert's equity investment in Recobia Therapeutics reflects the institute's commitment to fostering breakthrough innovations that do not only improve care and treatment of cancer but also revolution quality of life for patients. As a world-renowned cancer treatment and research centre based in Paris, Gustave Roussy brings not only capital but also unparalleled clinical expertise, patient cohorts, and translational research capabilities.

This strategic partnership will enable Recobia Therapeutics to:

- Advance clinical validation of its SC delivery platform in a world-class oncology environment
- Access Gustave Roussy's network of internationally recognized oncologists and researchers
- Accelerate the development of SC formulations for leading ADC candidates
- Leverage Gustave Roussy's infrastructure for early-phase clinical trials and translational studies.

Vincent Gass, board member at Recobia Therapeutics, quotes: "Gustave Roussy's decision to invest in Recobia is a tremendous endorsement of our technology and our vision. Having one of Europe's foremost cancer institutions as a partner gives us both the scientific credibility and the clinical robustness we need to progress our pipeline and deliver on our promise to make new immunotherapies accessible to everyone and everywhere by revolutionizing the way they are administered."



Gustave Roussy Transfert echoed his enthusiasm. "Subcutaneous administration of biotherapies represents a major opportunity to enhance patient comfort, reduce hospital burden, and improve treatment adherence. Recobia's hydrogel platform addresses a critical unmet need and we are proud to support its development as both a scientific partner and an investor," added Christophe Javaud, Executive Director at Gustave Roussy Transfert.

### **Background: The Case for Subcutaneous Oncology Delivery**

Most oncology biotherapies, including monoclonal antibodies and the rapidly growing class of ADCs, are currently administered intravenously (IV), requiring lengthy infusion sessions in hospital or clinic settings. SC administration offers compelling clinical and economic advantages, including shorter administration time, patient self-injection potential, and reduced healthcare resource utilization.


Recobia Therapeutics's proprietary platform is designed to overcome the key formulation and delivery barriers that have historically limited SC administration of biologics and particularly ADCs, positioning the company at the forefront of this emerging paradigm shift in oncology care.

### **About Recobia Therapeutics**

Recobia Therapeutics has been founded in 2022 in collaboration with ICANS, now Institut Strauss, as a preclinical-stage biotechnology-based start-up in Strasbourg. The company is pioneering a patented delivery platform for subcutaneous administration of high-dose monoclonal antibodies and antibody drug conjugates in oncology and hematology. Recobia Therapeutics wants to facilitate treatment access for oncology patients by transitioning biotherapies from intravenous to subcutaneous administration. The company has received support from SEMIA, Quest for Health and Paris Saclay Cancer Cluster (PSCC) and secured financing from the Grand Est Region, Bpifrance and Agence National de la Recherche (ANR).

### **About Gustave Roussy Transfert**

Founded in 2000, Gustave Roussy Transfert is the technology transfer and innovation arm of Gustave Roussy. Its mission is to identify and develop innovations emerging from the research teams based at Gustave Roussy, to establish and manage strategic translational



partnerships, and to source, promote, and support entrepreneurial projects arising from the Gustave Roussy ecosystem. <https://www.gustaveroussy.fr/fr/grt>

## About Gustave Roussy

Ranked first in France, first in Europe and sixth in the world, Gustave Roussy is a centre of global expertise entirely dedicated to patients living with cancer. The Institute is a founding pillar of the Paris-Saclay Cancer Cluster. Source of therapeutic innovations and diagnostic breakthroughs, the Institute welcomes more than 54,000 patients each year, including 2,760 children and adolescents, and develops an integrated approach combining research, care and teaching. An expert in rare cancers and complex tumours, Gustave Roussy treats all cancers at all stages of life. It offers its patients personalised care that combines innovation and humanity, taking into account both care and the physical, psychological and social quality of life. With 4,000 employees at two sites, Villejuif and Chevilly-Larue, Gustave Roussy brings together the expertise essential for high-level cancer research; 40.5% of treated patients are included in clinical studies. To find out more about Gustave Roussy and follow the Institute's news: [www.gustaveroussy.fr/en](http://www.gustaveroussy.fr/en) , X, Facebook, LinkedIn, Instagram et Bluesky.

## Contacts

### Recobia Therapeutics SAS

3 rue de la porte de l'Hopital  
67000 Strasbourg, France  
[info@recobiatx.com](mailto:info@recobiatx.com)  
<https://recobiatx.com/>

### Gustave Roussy

Claire Parisel and Léona Pinto  
[presse@gustaveroussy.fr](mailto:presse@gustaveroussy.fr)  
+33 1 42 11 50 59 - +33 1 42 11 63 59 - +33 6 17 66 00 26